HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Free Full Text (PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by FABER-ELMANN, A. Articles by MOZES, E. Search for Related Content PubMed PubMed Citation Articles by FABER-ELMANN, A. Articles by MOZES, E.

An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope

Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel

¹Correspondence: E-mail: edna.mozes{at}weizmann.ac.il

Myasthenia gravis (MG) is a T cell-regulated, antibody-mediated autoimmune disease. Immunization with two myasthenogenic peptides, p195–212 and p259–271, which are sequences of the human acetylcholine receptor, resulted in MG-associated immune responses. A dual altered peptide ligand (APL) composed of the two APLs of the myasthenogenic peptides inhibited, in vitro and in vivo, those responses. This study was aimed at understanding the mechanism(s) underlying the in vivo inhibitory properties of the dual APL. To this end, we analyzed T cells of mice that were immunized with p259–271 for their adhesiveness toward vascular cell adhesion molecule 1, for the activity of their secreted matrix metalloproteinases (MMPs), and for their intracellular phospholipase C (PLC) activity. Immunization with p259–271 triggered the above three activities and in vivo administration of the dual APL inhibited the latter. Thus, treatment of mice with the dual APL interferes with functions required for T cells to migrate and interact with the self-AChR. This is the first indication that very late antigen 4, MMP-9, and PLC are targets for immunomodulation of autoreactive T cells by altered peptide ligands.—Faber-Elmann, A., Grabovsky, V., Dayan, M., Sela, M., Alon, R., Mozes, E. An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope.

Key Words: autoimmune myasthenia gravis/T cell receptor/immunomodulation/T cell adhesiveness

This article has been cited by other articles:

				B. V. Aruna, M. Sela, and E. Mozes Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells PNAS, July 19, 2005; 102(29): 10285 - 10290. [Abstract] [Full Text] [PDF]

				H. Ben-David, M. Sela, and E. Mozes Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis PNAS, February 8, 2005; 102(6): 2028 - 2033. [Abstract] [Full Text] [PDF]

				M. Sela and E. Mozes Therapeutic vaccines in autoimmunity PNAS, October 5, 2004; 101(suppl_2): 14586 - 14592. [Abstract] [Full Text] [PDF]

				I. Caro-Aguilar, A. Rodriguez, J. M. Calvo-Calle, F. Guzman, P. De la Vega, M. Elkin Patarroyo, M. R. Galinski, and A. Moreno Plasmodium vivax Promiscuous T-Helper Epitopes Defined and Evaluated as Linear Peptide Chimera Immunogens Infect. Immun., July 1, 2002; 70(7): 3479 - 3492. [Abstract] [Full Text] [PDF]